Screener
Alamar Biosciences ALMR Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Alamar Biosciences in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Alamar Biosciences’s 10-Q, filed May 8, 2026.
- Filed
- May 8, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-213424
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net loss | $(21,325) | $(7,659) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization expense | 1,167 | 888 |
| Stock-based compensation | 1,467 | 619 |
| Accretion and amortization of premiums and discounts on investments, net | — | (208) |
| Loss on remeasurement of convertible notes | 8,594 | — |
| Convertible note issuance costs included in net income | 361 | — |
| Unrealized foreign exchange loss (gain) | 165 | (134) |
Item 1. Financial Statements
FAQ
- What is Alamar Biosciences's stock-based comp?
- Alamar Biosciences (ALMR) reported stock-based comp of $1.47M in Q1 2026.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Alamar Biosciences's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude